Investor Relations | Financial Information

Capex, Depeciation, R&D

U.S. GAAP IFRS
Unit:Yen millions / Fiscal Year FY2019 FY2020 FY2021 FY2022 FY2023
Investment in facilities Share of cash flow (%) 173,592
91.9
173,429
94.9
212,355
96.7
291,337
94.5
275,709
86.0
Depreciation expenses Share of net sales (%) 106,631
7.7
124,984
9.2
140,285
9.5
177,031
9.3
206,285
9.5
Cash flow (Net profit attributable to owners of parent + Depreciation expenses) 188,836 182,764 219,625 308,329 320,472
Research and development expenses Share of net sales (%) 115,155
8.3
117,489
8.6
127,046
8.6
165,250
8.7
179,467
8.2

Recommendations

  •  
  •  
  •